Farhana Sakloth's questions to SCYNEXIS (SCYX) leadership • Q2 2022
Question
On behalf of Michael Higgins, Farhana Sakloth asked for more details on the timing of FDA discussions for the IV formulation's Phase 1 data, the data readout timeline for the FURI and CARES studies, and the expected data readout for the VANQUISH study.
Answer
Chief Medical Officer Dr. David Angulo stated that the company is compiling the positive Phase 1 data for the IV formulation and aims to discuss a potential abbreviated development path with the FDA by the end of 2022. He clarified that data from the FURI and CARES studies are expected in 2024, intended to be part of a combined regulatory submission with the MARIO study. He also projected that data from the VANQUISH study would be available in the second half of 2024.